Cervical Cancer Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies

DelveInsight's, "Cervical Cancer Pipeline Insight" report provides comprehensive insights about 70+ companies and 70+ pipeline drugs in Cervical Cancer pipeline landscape. It covers the Cervical Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Cervical Cancer therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Stay ahead with the latest insights! Download DelveInsight's comprehensive Cervical Cancer Pipeline Report to explore emerging therapies, key Cervical Cancer Companies, and future Cervical Cancer treatment landscapes @ Cervical Cancer Pipeline Outlook Report [https://www.delveinsight.com/sample-request/cervical-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Key Takeaways from the Cervical Cancer Pipeline Report

* In February 2025:- GlaxoSmithKline:- The main purpose of this study was to evaluate the safety and reactogenicity of GlaxoSmithKline Biologicals SA (GSK)'s investigational adjuvanted human papillomavirus (HPV) vaccine formulations.
* In February 2025:- Seagen Inc.:- This is an open label, multi-center trial of tisotumab vedotin monotherapy and in combination with bevacizumab, pembrolizumab, or carboplatin in subjects with recurrent or stage IVB cervical cancer. The trial consists of two-parts a dose escalation part and an expansion part. The expansion part of the trial will be initiated once the Recommended Phase 2 Dose (RP2D) of the combinations have been determined in the dose escalation part.
* In February 2025:- Bio-Thera Solutions:- Phase II study: a study to explore the safety and preliminary efficacy of BAT1308 combined with platinum-based chemotherapy plus-minus Bevacizumab Phase III study: a confirmatory study to evaluate the safety and efficacy of BAT1308 combined with platinum-based chemotherapy plus-minus Bevacizumab as first-line therapy for PD-L1-positive (CPS greater than or equal to 1) persistent, recurrent or metastatic cervical cancer.
* In February 2025:- Hoffmann-La Roche:- The purpose of this study is to evaluate the efficacy and safety of tiragolumab in combination with atezolizumab and atezolizumab monotherapy in patients with programmed death-ligand 1 (PD-L1)-positive cervical cancer (metastatic and/or recurrent).
* DelveInsight's Cervical Cancer pipeline report depicts a robust space with 70+ active players working to develop 70+ pipeline therapies for Cervical Cancer treatment.
* The leading Cervical Cancer Companies such as Regeneron Pharmaceuticals, Jiangsu Hengrui Medicine, Akeso Biopharma, Celgene/MedImmune, Henlix Biotech, Zeria, Advaxis, AnGes, Advenchen Laboratories/Jiangsu Chia Tai Tianqing Pharmaceutical, Valent recombinant vaccine - National Vaccine and Serum Institute, Xiamen Innovax Biotech, Genentech, Bristol-Myers Squibb, Ono Pharmaceuticals, InnoMab, BeiGene, Agenus/Ludwig Institute for Cancer Research, EMD Serono, Merck, Apollomics, Immunitor, Arcus Biosciences, Guangzhou Gloria Biosciences, Taiho Pharmaceutical, Innovent Biologics, Clovis Oncology, Janssen, GlaxoSmithKline, Iovance Biotherapeutics , and others.
* Promising Cervical Cancer Therapies such as Granisetron, Ondansetron, Sorafenib, Cisplatin, Gemcitabine, and others.

Discover how the Cervical Cancer treatment paradigm is evolving. Access DelveInsight's in-depth Cervical Cancer Pipeline Analysis for a closer look at promising breakthroughs @ Cervical Cancer Clinical Trials and Studies [https://www.delveinsight.com/sample-request/cervical-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Cervical Cancer Emerging Drugs Profile

* Axalimogene filolisbac: Advaxis

Axalimogene filolisbac is a type of cancer vaccine being developed as immunotherapy that attacks HPV-associated cancers such as cervical cancers. It works by alerting the body's immune system to the presence of cancer, stimulating the body's natural defenses to attack the cancer. Axalimogene filolisbac is given intravenously and is being developed for the treatment of persistent, recurrent, or metastatic, squamous or non-squamous cell cervical cancer in patients who progress beyond first-li Phase III Study of ADXS11-001 Administered Following Chemoradiation as Adjuvant Treatment for High Risk Locally Advanced Cervical Cancer: AIM2CERV ne therapy. If licensed, Axalimogene filolisbac will offer a new treatment option for this patient group.

* Camrelizumab: Jiangsu HengRui Medicine Co., Ltd.

Camrelizumab (AiRuiKa Trademark ), a programmed cell death 1 (PD-1) inhibitor being developed by Jiangsu Hengrui Medicine Co. Ltd, recently received conditional approval in China for the treatment of relapsed or refractory classical Hodgkin lymphoma. The drug is also being investigated as a treatment for various other malignancies, including B cell lymphoma, oesophageal squamous cell carcinoma, gastric/gastroesophageal junction cancer, hepatocellular carcinoma, nasopharyngeal cancer and non-squamous, non-small cell lung cancer. The drug is currently being evaluated in Phase III clinical trial for the treatment of cervical cancer.

* AK104: Akeso

Cadonilimab (AK104) is a novel, potential next-generation, first-in-class bi-specific PD-1/CTLA-4 immuno-oncology backbone drug independently developed by the Company, and its major indications include liver cancer, cervical cancer, lung cancer, gastric cancer, esophageal squamous cell cancer and nasopharyngeal carcinoma. The preliminary research data of cervical cancer, gastric cancer and other tumors shows that, as compared with the combination therapy of PD-1 and CTLA-4, Cadonilimab has much lower toxicity and demonstrated promising safety profile and efficacy. In September 2020, National Medical Products Administration (the NMPA) of China has officially accepted the new drug application for the world's first-in-class Cadonilimab (PD-1/CTLA-4 bi-specific antibody, research and development code: AK104) for the treatment of relapsed or metastatic cervical cancer, which has received priority review.

* Durvalumab: AstraZeneca

A drug that binds to the protein PD-L1 to help immune cells kill cancer cells better and is used to treat different types of cancer. Durvalumab is used alone or with other drugs to treat adults with certain types of extensive-stage small cell lung cancer or stage III non-small cell lung cancer. It is also being studied in the treatment of other types of cancer. Durvalumab may block PD-L1 and help the immune system kill cancer cells. It is a type of monoclonal antibody and a type of immune checkpoint inhibitor. A Phase III clinical trial is being conducted for durvalumab to treat patients with cervical cancer.

* HLX10:Shanghai Henlius Biotech

HLX10, a novel recombinant humanised anti-programmed cell death protein 1 (PD-1) mAb independently developed by Henlius, has the potential to treat a variety of solid tumours. HLX10 has exhibited better pharmacokinetics, pharmacodynamics properties, favourable safety, tolerability profile and anti-tumor activity in preclinical and early clinical research studies. It is currently being investigated in Phase II stage of development to provide the potential treatment for cervical cancer.

The Cervical Cancer pipeline report provides insights into

* The report provides detailed insights about companies that are developing therapies for the treatment of Cervical Cancer with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Cervical Cancer Treatment.
* Cervical Cancer Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Cervical Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Cervical Cancer market.

Get a detailed analysis of the latest innovations in the Cervical Cancer pipeline. Explore DelveInsight's expert-driven report today! @ Cervical Cancer Unmet Needs [https://www.delveinsight.com/sample-request/cervical-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Cervical Cancer Companies

Regeneron Pharmaceuticals, Jiangsu Hengrui Medicine, Akeso Biopharma, Celgene/MedImmune, Henlix Biotech, Zeria, Advaxis, AnGes, Advenchen Laboratories/Jiangsu Chia Tai Tianqing Pharmaceutical, Valent recombinant vaccine - National Vaccine and Serum Institute, Xiamen Innovax Biotech, Genentech, Bristol-Myers Squibb, Ono Pharmaceuticals, InnoMab, BeiGene, Agenus/Ludwig Institute for Cancer Research, EMD Serono, Merck, Apollomics, Immunitor, Arcus Biosciences, Guangzhou Gloria Biosciences, Taiho Pharmaceutical, Innovent Biologics, Clovis Oncology, Janssen, GlaxoSmithKline, Iovance Biotherapeutics and others.

Cervical Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

* Inhalation
* Inhalation/Intravenous/Oral
* Intranasal
* Intravenous
* Intravenous/ Subcutaneous
* NA
* Oral
* Oral/intranasal/subcutaneous
* Parenteral
* Subcutaneous

Cervical Cancer Products have been categorized under various Molecule types such as

* Antibody
* Antisense oligonucleotides
* Immunotherapy
* Monoclonal antibody
* Peptides
* Protein
* Recombinant protein
* Small molecule
* Stem Cell
* Vaccine

Download DelveInsight's latest report to gain strategic insights into upcoming Cervical Cancer Therapies and key Cervical Cancer Developments @ Cervical Cancer Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/cervical-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Scope of the Cervical Cancer Pipeline Report

* Coverage- Global
* Cervical Cancer Companies- Regeneron Pharmaceuticals, Jiangsu Hengrui Medicine, Akeso Biopharma, Celgene/MedImmune, Henlix Biotech, Zeria, Advaxis, AnGes, Advenchen Laboratories/Jiangsu Chia Tai Tianqing Pharmaceutical, Valent recombinant vaccine - National Vaccine and Serum Institute, Xiamen Innovax Biotech, Genentech, Bristol-Myers Squibb, Ono Pharmaceuticals, InnoMab, BeiGene, Agenus/Ludwig Institute for Cancer Research, EMD Serono, Merck, Apollomics, Immunitor, Arcus Biosciences, Guangzhou Gloria Biosciences, Taiho Pharmaceutical, Innovent Biologics, Clovis Oncology, Janssen, GlaxoSmithKline, Iovance Biotherapeutics, and others.
* Cervical Cancer Therapies- Granisetron, Ondansetron, Sorafenib, Cisplatin, Gemcitabine , and others.
* Cervical Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Cervical Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Which companies are leading the race in Cervical Cancer drug development? Find out in DelveInsight's exclusive Cervical Cancer Pipeline Report-access it now! @ Cervical Cancer Emerging Drugs and Major Companies [https://www.delveinsight.com/sample-request/cervical-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Table of Content

* Introduction
* Executive Summary
* Cervical Cancer: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Cervical Cancer - DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* Axalimogene filolisbac : Advaxis
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II/III)
* QL 1604: Qilu Pharmaceutical
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I/II)
* NP 137: Netris Pharma
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* RTX 321: Rubius Therapeutics
* Drug profiles in the detailed report.....
* Inactive Products
* Cervical Cancer Key Companies
* Cervical Cancer Key Products
* Cervical Cancer- Unmet Needs
* Cervical Cancer- Market Drivers and Barriers
* Cervical Cancer- Future Perspectives and Conclusion
* Cervical Cancer Analyst Views
* Cervical Cancer Key Companies
* Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=cervical-cancer-clinical-trials-and-studies-ema-pdma-fda-approvals-mechanism-of-action-roa-nda-ind-and-companies]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/wolman-disease-market

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.